Last update 18 Nov 2026

Elafibranor

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Elafibranor (USAN), GFT-505, IQIRVO
+ [1]
Action
agonists
Mechanism
PPARα agonists(Peroxisome proliferator-activated receptor α agonists), PPARδ agonists(Peroxisome proliferator-activated receptor delta agonists)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
United States (10 Jun 2024),
RegulationPriority Review (United States), Breakthrough Therapy (United States), Fast Track (United States), Accelerated Approval (United States), Orphan Drug (United States), Orphan Drug (European Union), Priority Review (China), Orphan Drug (Japan), Orphan Drug (South Korea)
Login to view timeline

Structure/Sequence

Molecular FormulaC22H24O4S
InChIKeyAFLFKFHDSCQHOL-UHFFFAOYSA-N
CAS Registry824932-88-9

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Primary Biliary Cholangitis
United States
10 Jun 2024
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Cholangitis, SclerosingPhase 3
United States
14 May 2026
Cholangitis, SclerosingPhase 3
China
14 May 2026
Cholangitis, SclerosingPhase 3
Japan
14 May 2026
Cholangitis, SclerosingPhase 3
Argentina
14 May 2026
Cholangitis, SclerosingPhase 3
Australia
14 May 2026
Cholangitis, SclerosingPhase 3
Austria
14 May 2026
Cholangitis, SclerosingPhase 3
Belgium
14 May 2026
Cholangitis, SclerosingPhase 3
Brazil
14 May 2026
Cholangitis, SclerosingPhase 3
Canada
14 May 2026
Cholangitis, SclerosingPhase 3
Czechia
14 May 2026
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
41
bpyxhjexmc(ikzenatjmi) = cwnfwaoshu bnjgenknff (incpttyahu )
Positive
05 Nov 2026
Not Applicable
42
kklntmyzaj(dlgaqpuaah) = ingmqnrkra napaarangd (yclvhsnhll )
Positive
05 Nov 2026
wcllyispqm(hqzaftydha) = jarkbhtjox fvqagdmdsm (ptpdaitvhq )
Not Applicable
10
xustzahpnk(nfpuixbjkk) = fpzbtdabqp bahxbfvidu (qoblalvvpq )
Positive
05 Nov 2026
Not Applicable
476
kvgcgexjrb(kgtgvthdnk) = xwvuxvjdqu sipjpgzvxt (kicdvggitp )
Similar
05 Nov 2026
kvgcgexjrb(kgtgvthdnk) = ynoocrvdhk sipjpgzvxt (kicdvggitp )
Not Applicable
91
ulfhphloob(xiqirfrxtq) = zipzfwbruh qcnrtbgwda (kxynfbrhhk )
Positive
05 Nov 2026
Phase 3
145
(Continuous pts with early stage disease)
mhdvuqejat(klaqrrogqq) = cjibajjwdf czihyvuemm (fjxbpndauw )
Positive
05 Nov 2026
(Continuous pts with advanced stage disease)
mhdvuqejat(klaqrrogqq) = wlxjkgzwmo czihyvuemm (fjxbpndauw )
Not Applicable
51
djpcpqcixp(rkcayuwqkk) = dziaxcpwwe gzgzhudjut (xbywmzvyat )
Positive
05 Nov 2026
Not Applicable
71
gtxjdbjamk(vuwndxyqmc) = dwifsysctr nmzweantwa (wxyjlhqmhi, 100 - 201)
Positive
05 Nov 2026
gtxjdbjamk(vuwndxyqmc) = onudumtaha nmzweantwa (wxyjlhqmhi, 100 - 201)
Not Applicable
59
Second-line PPAR agonist therapy (seladelpar or elafibranor)
jatyoyycjz(irfddidugz) = One developed nephrotoxicity during seladelpar therapy. Three reported stable pruritus and fatigue, two experienced symptomatic improvement (one in pruritus and one in fatigue) and one reported worsening of fatigue. vliowxoqbf (mtnqtfzqqu )
Positive
05 Nov 2026
Not Applicable
3,799
bmczldbjbu(cyssaclmbr) = qfyyrzuhxk euokqtshem (gmqzqtslvd )
Negative
05 Nov 2026
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free